Researchers study drug for Alzheimer's stem cell treatment

04/24/2006 | United Press International

U.S. researchers say Axonyx's Posiphen was found to improve the ability of transplanted human neuronal stem cells to change into neurons in biotech mice. They say the Phase I trial drug appears to suppress the amyloid precursor protein, allowing new neurons to be produced in the brain, a critical development toward a stem cell therapy for Alzheimer's.

View Full Article in:

United Press International

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Senior director risk adjustor and coding doc
Novant Health
Charlotte, NC
Associate Director, Promotion Integrity
Bristol-Myers Squibb
Plainsboro, NJ
Vice President, Medicare Advantage
BCBS-Louisiana
Baton Rouge, LA